PRESS RELEASE
NH TherAguix Announces Publication of Groundbreaking Study on AGuIX®
Nanoparticles Enhancing Cervical Cancer Treatment
* Key clinical milestone showcasing the potential of AGuIX®, a next-generation
nanodrug developed by NH TherAguix to improve tumor targeting and augment
efficacy when combined with chemoradiation and brachytherapy.
* Phase I clinical trial results demonstrate safety, tolerance, and promising
therapeutic outcomes in locally advanced cervical cancer patients.
Paris, France, Wednesday July 3(rd), 2024 - NH TherAguix (NHT), a phase II
clinical-stage biotechnology company specializing in the development of novel
nanomedicine solutions for precision radiotherapy in oncology, today announced
the publication of a pioneering study in American Chemical Society (ACS) Nano, a
high impact factor journal. The study, titled "Theragnostic gadolinium-based
nanoparticles safely augment X-ray radiation effects in patients with cervical
cancer", provides compelling evidence supporting the use of AGuIX® nanoparticles
to selectively enhance the effectiveness of radiotherapy in cervical cancer
treatment.
AGuIX®: A nanodrug capable of improving the precision and effectiveness of
radiotherapy
The culmination of over a decade of research, AGuIX® nanoparticles are designed
to meet the critical medical need for more effective cancer treatments,
including advanced cervical cancer. These gadolinium-based nanoparticles enhance
MRI contrast, allowing for precise tumor visualization, and significantly
amplify the radiation dose delivered to tumor tissues, thereby improving the
efficacy of radiotherapy.
Study Highlights:
* Safety and Tolerance: The Phase I clinical trial involving 12 patients with
locally advanced cervical cancer demonstrated that AGuIX® nanoparticles have
an excellent safety profile, with no dose-limiting toxicities and no severe
side effects observed, especially when combined with brachytherapy or
cisplatinum-based chemoradiation.
* Enhanced Imaging and Treatment: Based on AGuIX® quantification through MRI,
treating physicians can determine the optimal radiotherapy dose for each
patient.
* Efficacy: All patients (n=12) achieved complete remission of the primary
tumor, with only one instance of distant tumor recurrence, i.e. 8% compared
to 30-40% recurrence according to historical studies. The study confirms the
relationship between tumor accumulation, quantification, and encouraging
tumor response signals: an estimated dose enhancement factor of about 15% at
2 Gy per tumor has been observed, a meaningful increase that generates a
biological response sufficient to achieve tumor control and improved
outcomes for patients.
* Rapid Clearance: The nanoparticles are rapidly cleared from the body,
minimizing potential side effects and allowing for efficient imaging and
treatment cycles.
Dr. Olivier de Beaumont, CMO of NH TherAguix, emphasized the significance of
these findings: "This study marks a significant advancement in the use of AGuIX®
as a novel option for cancer treatment. The ability to quantify AGuIX®
concentration in correspondence with tumor response signals with high precision
opens new avenues for personalized medicine in oncology using companion MRI-
based information."
Vincent Carrère, CEO of NH TherAguix, commented: "We are thrilled to announce
this important publication in ACS Nano. I would like to thank the teams at IGR,
especially Professors C. Chargari and E. Deutsch, for this remarkable clinical
and translational work. It highlights the transformative potential of AGuIX® in
enhancing radiotherapy for cervical cancer patients. These promising results
reinforce our commitment to advancing innovative cancer treatments and improving
patient outcomes."
About NH TherAguix: www.nhtheraguix.com (http://www.nhtheraguix.com)
NH TherAguix is a late-stage biotech company developing AGuIX® to treat tumors
and metastases in patients undergoing radiotherapy. It is estimated that
approximately 60% of cancer patients receive radiotherapy. AGuIX® is currently
being assessed in multiple Phase II randomized trials across various cancer
types, including brain metastases, glioblastoma, and pancreatic and lung
cancers.
To date, over 190 patients have been treated with AGuIX®. This innovation is
protected by 18 patent families and has been extensively tested in various
preclinical models, with results published in more than 80 high-impact
publications.
NH TherAguix was established in 2015 following 10 years of academic research
that led to the invention of AGuIX® and the discovery of its radiosensitizing
effect. The company has raised approximately EUR40m of funds, including a EUR13m
Series A in 2019 led by Bpifrance with Arbevel, Omnes, and Supernova.
Media contacts:
NH TherAguix
NewCap - Arthur Rouillé
arouille@newcap.fr (mailto:arouille@newcap.fr)
+33 (0)1 44 71 00 15
Â